The effects and efficacy of Lerochol (Lerodalcibep-liga)

Lerochol (Lerodalcibep-liga) is a new third-generation PCSK9 inhibitor , which belongs to recombinant fusion protein engineering. The drug's main ingredient is lerodalcibep, which is designed to be a specific PCSK9-binding domain fused to human serum albumin (HSA), commonly known as an attachment protein. PCSK9 is an important protein that plays a key regulatory role in cholesterol metabolism. Its main function is to promote the lysosomal degradation of low-density lipoprotein receptor (LDLR) on the surface of hepatocytes.

In patients with hypercholesterolemia,PCSK9 activity is often overactive, leading to accelerated degradation of LDLR, thereby reducing the liver's ability to clear circulating low-density lipoprotein cholesterol (LDL-C). Lerodalcibep effectively prevents the degradation of LDLR by inhibiting the interaction between PCSK9 and LDLR. This mechanism increases the abundance and recycling of LDLR, thereby significantly improving the liver's clearance rate of LDL-C and helping patients reduce blood cholesterol levels.

In addition,The fusion of lerodalcibep and human serum albumin not only enhances the stability of the drug, but also plays an important role in pharmacokinetics. By preventing the rapid elimination of the drug in the kidneys and prolonging its half-life in the plasma, lerodalcibep can achieve a more convenient administration method and reduce the burden of frequent drug use on patients. Compared with natural peptide drugs, the dosing schedule of this drug is more flexible, which can help improve patients' medication compliance and thereby improve treatment effects.

The clinical application of Lerochol has gradually demonstrated its unique advantages, especially in the treatment of hypercholesterolemia and related cardiovascular diseases. Relevant studies have shown that the use of Lerochol can significantly reduce patients' LDL-C levels, thereby reducing the risk of cardiovascular events and improving patients' quality of life. As research on PCSK9 inhibitors continues to deepen, Lerochol may become a new option for the prevention and treatment of cardiovascular diseases.

Reference materials:https://go.drugbank.com/drugs/DB19071